HSP-dependent protection against gastrointestinal diseases

Tohru Mizushima

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

It is well known that heat shock proteins (HSPs) are induced by various stressors in order to confer protection against such stressors. Since stressor-induced tissue damage is involved in various diseases, especially gastrointestinal diseases, such as gastric ulcer, it has been thought that HSPs are protective against these diseases. Indirect lines of evidence, such as identification of geranylgeranylacetone (GGA, a leading anti-ulcer drug in Japanese market) as non-toxic HSP-inducer, suggest that HSPs provide a major protective mechanism against irritant-induced gastric lesions. However, no direct evidences that support this notion exits. Furthermore, because GGA has other gastroprotective effects, it was not clear whether HSP-induction by GGA is the main mechanism for its anti-ulcer effect. In this article, I review our recent work on protective roles of HSPs against gastrointestinal diseases, using transgenic mice. We obtained genetic evidence showing not only that HSPs are protective against irritant-induced gastric lesions but also that GGA achieves its anti-ulcer effect through induction of HSPs. We also obtained genetic evidence that HSPs are protective against inflammatory bowel disease (IBD)-related colitis and lesions of small intestine. Furthermore, we found that GGA is effective against these diseases. Based on these observations, we propose that non-toxic HSP-inducers, such as GGA are therapeutically beneficial for these diseases.

Original languageEnglish
Pages (from-to)1190-1196
Number of pages7
JournalCurrent Pharmaceutical Design
Volume16
Issue number10
DOIs
Publication statusPublished - 2010 Apr
Externally publishedYes

Fingerprint

Gastrointestinal Diseases
Heat-Shock Proteins
geranylgeranylacetone
Irritants
Ulcer
Stomach
Anti-Ulcer Agents
Colitis
Stomach Ulcer
Inflammatory Bowel Diseases
Transgenic Mice
Small Intestine

Keywords

  • Gastric ulcer
  • GGA
  • HSF1
  • HSP70
  • IBD
  • Lesions of the small intestine

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

HSP-dependent protection against gastrointestinal diseases. / Mizushima, Tohru.

In: Current Pharmaceutical Design, Vol. 16, No. 10, 04.2010, p. 1190-1196.

Research output: Contribution to journalArticle

Mizushima, Tohru. / HSP-dependent protection against gastrointestinal diseases. In: Current Pharmaceutical Design. 2010 ; Vol. 16, No. 10. pp. 1190-1196.
@article{6624992b3320417386d796b3b84c207e,
title = "HSP-dependent protection against gastrointestinal diseases",
abstract = "It is well known that heat shock proteins (HSPs) are induced by various stressors in order to confer protection against such stressors. Since stressor-induced tissue damage is involved in various diseases, especially gastrointestinal diseases, such as gastric ulcer, it has been thought that HSPs are protective against these diseases. Indirect lines of evidence, such as identification of geranylgeranylacetone (GGA, a leading anti-ulcer drug in Japanese market) as non-toxic HSP-inducer, suggest that HSPs provide a major protective mechanism against irritant-induced gastric lesions. However, no direct evidences that support this notion exits. Furthermore, because GGA has other gastroprotective effects, it was not clear whether HSP-induction by GGA is the main mechanism for its anti-ulcer effect. In this article, I review our recent work on protective roles of HSPs against gastrointestinal diseases, using transgenic mice. We obtained genetic evidence showing not only that HSPs are protective against irritant-induced gastric lesions but also that GGA achieves its anti-ulcer effect through induction of HSPs. We also obtained genetic evidence that HSPs are protective against inflammatory bowel disease (IBD)-related colitis and lesions of small intestine. Furthermore, we found that GGA is effective against these diseases. Based on these observations, we propose that non-toxic HSP-inducers, such as GGA are therapeutically beneficial for these diseases.",
keywords = "Gastric ulcer, GGA, HSF1, HSP70, IBD, Lesions of the small intestine",
author = "Tohru Mizushima",
year = "2010",
month = "4",
doi = "10.2174/138161210790945986",
language = "English",
volume = "16",
pages = "1190--1196",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - HSP-dependent protection against gastrointestinal diseases

AU - Mizushima, Tohru

PY - 2010/4

Y1 - 2010/4

N2 - It is well known that heat shock proteins (HSPs) are induced by various stressors in order to confer protection against such stressors. Since stressor-induced tissue damage is involved in various diseases, especially gastrointestinal diseases, such as gastric ulcer, it has been thought that HSPs are protective against these diseases. Indirect lines of evidence, such as identification of geranylgeranylacetone (GGA, a leading anti-ulcer drug in Japanese market) as non-toxic HSP-inducer, suggest that HSPs provide a major protective mechanism against irritant-induced gastric lesions. However, no direct evidences that support this notion exits. Furthermore, because GGA has other gastroprotective effects, it was not clear whether HSP-induction by GGA is the main mechanism for its anti-ulcer effect. In this article, I review our recent work on protective roles of HSPs against gastrointestinal diseases, using transgenic mice. We obtained genetic evidence showing not only that HSPs are protective against irritant-induced gastric lesions but also that GGA achieves its anti-ulcer effect through induction of HSPs. We also obtained genetic evidence that HSPs are protective against inflammatory bowel disease (IBD)-related colitis and lesions of small intestine. Furthermore, we found that GGA is effective against these diseases. Based on these observations, we propose that non-toxic HSP-inducers, such as GGA are therapeutically beneficial for these diseases.

AB - It is well known that heat shock proteins (HSPs) are induced by various stressors in order to confer protection against such stressors. Since stressor-induced tissue damage is involved in various diseases, especially gastrointestinal diseases, such as gastric ulcer, it has been thought that HSPs are protective against these diseases. Indirect lines of evidence, such as identification of geranylgeranylacetone (GGA, a leading anti-ulcer drug in Japanese market) as non-toxic HSP-inducer, suggest that HSPs provide a major protective mechanism against irritant-induced gastric lesions. However, no direct evidences that support this notion exits. Furthermore, because GGA has other gastroprotective effects, it was not clear whether HSP-induction by GGA is the main mechanism for its anti-ulcer effect. In this article, I review our recent work on protective roles of HSPs against gastrointestinal diseases, using transgenic mice. We obtained genetic evidence showing not only that HSPs are protective against irritant-induced gastric lesions but also that GGA achieves its anti-ulcer effect through induction of HSPs. We also obtained genetic evidence that HSPs are protective against inflammatory bowel disease (IBD)-related colitis and lesions of small intestine. Furthermore, we found that GGA is effective against these diseases. Based on these observations, we propose that non-toxic HSP-inducers, such as GGA are therapeutically beneficial for these diseases.

KW - Gastric ulcer

KW - GGA

KW - HSF1

KW - HSP70

KW - IBD

KW - Lesions of the small intestine

UR - http://www.scopus.com/inward/record.url?scp=77950914949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950914949&partnerID=8YFLogxK

U2 - 10.2174/138161210790945986

DO - 10.2174/138161210790945986

M3 - Article

VL - 16

SP - 1190

EP - 1196

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 10

ER -